Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
Zsuzsanna Bago-horvath
Clinical Cancer Research, 2019
View PDFchevron_right
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients
M. Gnant
British journal of cancer, 2013
View PDFchevron_right
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
Kenjiro Aogi
ESMO open, 2018
View PDFchevron_right
Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer
Jean-marc Ferrero
Research Square (Research Square), 2023
View PDFchevron_right
Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients
andrea villasco
Breast Cancer
View PDFchevron_right
A Non-randomized, Observational Trial of Short-term Preoperative Endocrine Therapy in ER Positive Breast Cancer to Investigate Changes in Genomic Expression Using the Oncotype DX® Recurrence Score®
Bernadette Glenn-Porter
View PDFchevron_right
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
Annuska Glas
Breast Cancer Research and Treatment
View PDFchevron_right
Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself
Lissandra Lago
International Journal of Gynecological Cancer, 2006
View PDFchevron_right
Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
Anastasia Constantinidou
Clinical Cancer Research
View PDFchevron_right
Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study
Jean-marc Ferrero
European Journal of Cancer, 2019
View PDFchevron_right
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial
Christos Markopoulos
JNCI: Journal of the National Cancer Institute, 2017
View PDFchevron_right
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
Jérôme Lemonnier
British Journal of Cancer
View PDFchevron_right
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
A. Goldhirsch, Alan Coates
Annals of Oncology, 2009
View PDFchevron_right
Preventing metastatic recurrence in low-risk ER/PR+ breast cancer patients – a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy
james stahl
View PDFchevron_right
Clinical validation of the EndoPredict test in node-positive chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM/9906 trial
Rosalía Caballero, Lourdes Calvo
Breast Cancer Research, 2014
View PDFchevron_right
280MO Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study
Pauline Corbaux
Annals of Oncology, 2020
View PDFchevron_right
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
S. Lax
British Journal of Cancer, 2015
View PDFchevron_right
The combined endocrine receptor (CER) is a better discriminator of patient outcome than ER and PR alone
Zahra Mohammed
International Journal of Surgery, 2016
View PDFchevron_right
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
N. Wilcken
The New England journal of medicine, 2017
View PDFchevron_right
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer
Sara Bravaccini
Medicine, 2020
View PDFchevron_right
The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs
Naruto Taira
Breast Cancer, 2020
View PDFchevron_right
Data from Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR<sup>+</sup>/HER2<sup>−</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
Saul Campos-Gomez
2023
View PDFchevron_right
Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers
Cigdem Selli
View PDFchevron_right
Predictors of response to second-line endocrine therapy for breast cancer
Sarah Pinder
Breast Cancer Research and Treatment, 1997
View PDFchevron_right
Breast cancer: are long-term and intermittent endocrine therapies equally effective?
Rebecca Emeny
Journal of Cancer Research and Clinical Oncology, 2020
View PDFchevron_right
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy
Tadahiko Shien
The Breast, 2007
View PDFchevron_right
Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
samuel martel
ESMO Open, 2020
View PDFchevron_right
Completion of 5-year adjuvant endocrine therapy in the community
Boikanyo Makubate
Breast Cancer Research, 2010
View PDFchevron_right
Optimizing adjuvant endocrine therapy for early ER+ breast cancer: An update for surgeons
Leon Mokbel
American journal of surgery, 2018
View PDFchevron_right
Endocrine Therapy in Metastatic Breast Cancer
rosalba amodio
Annals of the New York Academy of Sciences, 2009
View PDFchevron_right
Selecting Endocrine Therapy for Breast Cancer: What Role Does HER-2/neu Status Play?
Tatiana Prowell
Seminars in Oncology, 2006
View PDFchevron_right
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Fabio Franke
New England Journal of Medicine
View PDFchevron_right
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
Ivana Sestak
Journal of Clinical Oncology, 2014
View PDFchevron_right
Data from Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>−</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
Zsuzsanna Bago-horvath
2023
View PDFchevron_right
The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER+/HER2− Breast Cancer Stratified as Having Moderate or Poor Prognosis by Nottingham Prognostic Index
Umar Wazir
Anticancer Research, 2018
View PDFchevron_right